


5 WE CLAIM:

1. A compound of formula (I)



(I)

wherein

- 10 Cy is a non-aromatic carbocycle or heterocycle optionally substituted with hydroxyl, mercapto, thioalkyl, halogen, oxo, thio, amino, aminoalkyl, amidine, guanidine, nitro, alkyl, alkoxy or acyl;
- 15 X is a divalent hydrocarbon chain optionally substituted with hydroxyl, mercapto, halogen, amino, aminoalkyl, nitro, oxo or thio and optionally interrupted with N, O, S, SO or SO₂;
- 20 Y is a carbocycle or heterocycle optionally substituted with hydroxyl, mercapto, halogen, oxo, thio, thioalkyl, amino, aminoalkyl, carbocycle or heterocycle ring, hydrocarbon, a halo-substituted hydrocarbon, amino, amidine, guanidine, cyano, nitro, alkoxy or acyl;
- 25 L is a bond or a divalent hydrocarbon chain optionally substituted hydroxyl, halogen, oxo or thio and optionally interrupted with N, O, S, SO or SO₂ or an amino acid residue; less than 3 or 5 atoms
- 30 R₁ is H, OH, amino, O-carbocycle or alkoxy optionally substituted with amino, a carbocycle or heterocycle;

5 R₂₋₅ are independently H, hydroxyl, mercapto,
 halogen, cyano, amino, amidine, guanidine, nitro
 or alkoxy; or R₃ and R₄ together form a fused
 carbocycle or heterocycle optionally substituted
 with hydroxyl, halogen, oxo, thio, amino, amidine,
10 guanidine or alkoxy;
 R₆ is H or a hydrocarbon chain optionally substituted
 with a carbocycle or a heterocycle; and
 salts, solvates and hydrates thereof;
 with the proviso that when Y is phenyl, R₂, R₄ and R₅
15 are H, R₃ is Cl and R₁ is OH then X is other than
 cyclohexyl.

2. A compound according to claim 1, wherein Cy is a 5-
 or 6-member non-aromatic heterocycle optionally
20 substituted with hydroxyl, mercapto, thioalkyl
 halogen, oxo, thio, amino, aminoalkyl, amidine,
 guanidine, nitro, alkyl, alkoxy or acyl.

3. A compound according to claim 2, wherein said
25 heterocycle comprises one or two heteroatoms and is
 optionally substituted with hydroxyl, oxo, mercapto,
 thio, alkyl or alkanoyl.

4. A compound according to claim 3, wherein said
30 heterocycle is selected from the group consisting of
 piperidine, piperazine, morpholine, tetrahydrofuran,
 tetrahydrothiophene, oxazolidine, cyclopropa-
 pyrrolidine and thiazolidine optionally substituted
 with hydroxy, oxo, mercapto, thio, alkyl or
35 alkanoyl.

5. A compound according to claim 4, wherein said
 heterocycle is selected from the group consisting of

- 5 piperidine, piperazine, morpholine, tetrahydrofuran,
 tetrahydrothiophene, oxazolidine, thiazolidine
 optionally substituted with hydroxy, oxo, mercapto,
 thio, alkyl or alkanoyl.
- 10 6. A compound according to claim 1, wherein Cy is a 3-6
 member carbocycle optionally substituted with
 hydroxyl, mercapto, halogen, oxo, thio, amino,
 amidine, guanidine, alkyl, alkoxy or acyl.
- 15 7. A compound according to claim 6, wherein said
 carbocycle is partially unsaturated.
8. A compound according to claim 7, wherein Cy is
 cyclopropyl, cyclypropenyl, cyclobutyl, cyclbutenyl,
20 cyclopentyl, cyclopentenyl cyclohexyl or
 cyclohexenyl.
9. A compound according to claim 1, wherein X is a C₁₋₅
 divalent hydrocarbon optionally having one or more
25 carbon atoms replaced with N, O, S, SO or SO₂ and
 optionally being substituted with hydroxyl, oxo or
 thio.
10. A compound according to claim 1, wherein X is -CH₂-
30 NR₆-C(O)- wherein the carbonyl -C(O)- portion thereof
 is covalently bound to Cy and R₆ is H or alkyl.
11. A compound according to claim 1, wherein Y is a
 carbocycle or heterocycle optionally substituted
35 with hydroxyl or halogen.
12. A compound according to claim 11, wherein Y is
 furan-2-yl, thiophene-2-yl or phenyl, wherein said

5 phenyl is optionally substituted with halogen or
hydroxyl.

13. A compound according to claim 1, wherein L is a
divalent hydrocarbon optionally having one or more
10 carbon atoms replaced with N, O, S, SO or SO₂ and
optionally being substituted with hydroxyl, halogen
oxo or thio; or three carbon atoms of the
hydrocarbon are replaced with an amino acid residue.

14. A compound according to claim 13, wherein L is -
CH=CH-C(O)-NR₆-CH₂-, -CH₂-NR₆-C(O)-, -C(O)-NR₆-CH₂-, -
CH(OH)-(CH₂)₂-, -(CH₂)₂-CH(OH)-, -(CH₂)₃-, -C(O)-NR₆-
CH(R₇)-C(O)-NR₆-, -NR₆-C(O)-CH(R₇)-NR₆-C(O)-, -CH(OH)-
CH₂-O- or -CH(OH)-CF₂-CH₂- wherein each R₆ is
20 independently H or alkyl and R₇ is an amino acid
side chain.

15. A compound according to claim 14, wherein R₁ is H,
OH, amino, O-carbocycle or alkoxy optionally
25 substituted with a carbocycle.

16. A compound according to claim 15, wherein R₁ is H or
C₁₋₄ alkyloxy.

17. A compound according to claim 1, wherein at least
one of R₂ and R₃ is halogen and the other is H or
30 halogen.

18. A compound according to claim 17, wherein R₂ and R₃
35 are both Cl.

19. A compound according to claim 18, wherein R₄ and R₅
are both H.

20. A pharmaceutical composition comprising a compound according to claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

21. A method of inhibiting binding of a LFA-1 to a protein ligand comprising contacting LFA-1 with a compound of claim 1.

22. A method of treating a disease or condition mediated by LFA-1 in a mammal comprising administering to said mammal an effective amount of a compound according to claim 1.

23. A method according to claim 23, wherein said disease or condition is arthritis, psoriasis, organ transplant rejection, asthma, and inflammatory bowel disease

23. A method of inhibiting an inflammatory disease or condition in a mammal comprising administering to said mammal an effective amount of a compound according to claim 1.